Cytokinetics, Incorporated
Every calculator, already run for CYTK
Open the full toolkit →You have the numbers on CYTK. Get the argument.
A written report on which of these readings actually decide the outcome for Cytokinetics, Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
22 analysts covering CYTKAnalyst Price Target Disagreement for Cytokinetics, Incorporated
Wall Street's bull case implies +123% from the current price; the bear case implies +30%. A 93% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CYTK
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and…
CYTK — frequently asked
Is CYTK a buy right now?
Wall Street's consensus rating on Cytokinetics, Incorporated is Strong Buy across 22 analysts, with a mean price target of $109.90 (+68% vs. the current $65.60). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CYTK's next earnings date?
Cytokinetics, Incorporated is next scheduled to report earnings around Nov 5, 2026. A full CYTK research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Cytokinetics, Incorporated?
Analysts covering Cytokinetics, Incorporated (CYTK) range from a bear-case target of $85.00 to a bull-case high of $146.00, with a mean consensus target of $109.90 across 20 analysts. The spread of $61.00 (93% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Cytokinetics, Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Cytokinetics, Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CYTK research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Cytokinetics, Incorporated, in minutes. 3 free reports included with every account — no credit card required.